[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus].
Gurevich
M A
MA
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D048909:Diabetes Complications / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D001241:Aspirin; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004232:Diuretics; D006442:Glycated Hemoglobin; D000960:Hypolipidemic Agents; D007211:Indoles; D010975:Platelet Aggregation Inhibitors; D014700:Verapamil; C052035:trandolapril